Topical Simvastatin for Treating Infantile Hemangioma

Inclusion Criteria: * Healthy children aged between 3 months and 5 years. * Newly diagnosed superficial IH or experiencing rebound growth with a superficial component. * Participants must possess at least one IH lesion with the longest diameter equal to or greater than 2 cm, located on any part of the body except the lips. * Participants must not have received any of the following treatments for their IH: * Topical medical therapy within the past 2 weeks. * Systemic medical therapy within the past 3 months. * Laser treatment within the past 6 weeks. * Written informed consent from the parent(s)/guardian(s) of minor participants must be obtained before any study procedure is performed. Exclusion Criteria: * IH is primarily characterized as subcutaneous, and deep, with minimal cutaneous involvement for evaluation. * IH with active ulceration. * IH to be treated involving the lips mainly. * Participants with concurrent skin conditions that may impede accurate clinical assessment of the IH. * Participants with hereditary or metabolic disorders requiring systemic statin therapy. * Participants who are allergic to statins, or other ingredients present in the topical medication.